Theriva Biologics Inc. Market Cap ($8.58 Million)
Market Cap & Net Worth: Theriva Biologics Inc. (TOVX)
Theriva Biologics Inc. market cap. Theriva Biologics Inc. (NYSE MKT:TOVX) has a market capitalization of $8.58 Million ($8.58 Million) as of October 30, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #27364 globally and #5686 in its home market, demonstrating a -4.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theriva Biologics Inc.'s stock price $0.19 by its total outstanding shares 45892668 (45.89 Million).
Theriva Biologics Inc. Market Cap History (2015–2026)
Theriva Biologics Inc. market cap history from 2015 to 2026. Data shows change from $919.57 Billion to $8.58 Million (-65.16% CAGR). Check Theriva Biologics Inc. share price for real-time trading data and today's change.
Theriva Biologics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theriva Biologics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see TOVX cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TOVX by Market Capitalization
Companies near Theriva Biologics Inc. in the global market cap rankings as of October 30, 2026. See TOVX net asset quality score to understand what proportion of total assets are financed by equity.
Key companies related to Theriva Biologics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Theriva Biologics Inc. (2015–2026)
Market capitalization of Theriva Biologics Inc. from 2015 to today. Between 2015 and today, Theriva Biologics Inc.'s market cap moved from $919.57 Billion to $ 8.58 Million, with a yearly change of -65.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.58 Million | -10.95% |
| 2025 | $9.64 Million | -88.00% |
| 2024 | $80.31 Million | -83.72% |
| 2023 | $493.35 Million | -4.44% |
| 2022 | $516.29 Million | -83.33% |
| 2021 | $3.10 Billion | -28.95% |
| 2020 | $4.36 Billion | -25.49% |
| 2019 | $5.85 Billion | -8.93% |
| 2018 | $6.42 Billion | -96.86% |
| 2017 | $204.80 Billion | -32.89% |
| 2016 | $305.19 Billion | -66.81% |
| 2015 | $919.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Theriva Biologics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.58 Million USD |
| MoneyControl | $8.58 Million USD |
| MarketWatch | $8.58 Million USD |
| marketcap.company | $8.58 Million USD |
| Reuters | $8.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more